报价延迟最少15分钟:2025/09/03 19:24 EDT
盘后时段
|
||||
|
50 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
51.84
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.13/-1.77
|
|
企业价值
11.28B
|
| 资产负债 |
|
每股账面净值
-9.35
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
9.30M
|
|
每股收益
0.05
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/03 19:24 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
